A newly peer-reviewed manuscript addresses thyroid monitoring following intravascular iodinated contrast media exposure in infants and young children. This consensus-based publication was developed in response to the U.S. Food and Drug Administration’s 2022 Drug Safety Communication recommending thyroid function monitoring in children up to 3 years of age after iodinated contrast–enhanced imaging. The manuscript resulted from discussions among a multidisciplinary collection of pediatric endocrinology and imaging experts. The manuscript critically reviews the existing evidence on iodine-associated thyroid dysfunction in early childhood and offers practical guidance on post-exposure thyroid testing and management. Importantly, the authors identify substantial gaps in current knowledge and strongly advocate for well-designed prospective studies to better define the incidence, risk factors, natural history, and outcomes of thyroid dysfunction in this vulnerable population. Dr. Pesce from our division was one of the participating experts and authors of the manuscript. This reflects her commitment to advancing evidence-based guidance at the intersection of pediatric thyroid management and clinical policy, and we congratulate her and the full author team on this impactful contribution to pediatric care. The abstract is indexed on PubMed and can be found here.
